According to our new market research study on “Typhoid fever vaccines Market to 2027 – Global Analysis and Forecast – by vaccine type and route of administration,” the market is expected to reach US$ 525.32 million by 2027 from US$ 262.81 million in 2019. The market is estimated to grow with a CAGR of 9.3% from 2020 to 2027. The report highlights trends prevailing in the market, and drivers and hindrances pertaining to the market growth.
Segments – By Type:
Based on vaccine type, the market is segmented in to live attenuated vaccine, capsular polysaccharide vaccines, conjugate vaccine, and others. In 2019, the capsular polysaccharide vaccines segment accounted for the highest share of the market. Growth of this segment is attributed to the effectiveness associated with in preventing infections and increasing patient pool across the globe. The Live Attenuated Vaccine segment is likely to register highest CAGR in the global Typhoid fever vaccines market during the forecast period.
Download PDF Sample Copy at:
Based on route of administration, the Typhoid fever vaccines market is segmented into oral and injections. The injectable segment held the largest share of the market in 2019, whereas the oral segment is anticipated to register the highest CAGR of 10.1% in the market during the forecast period.
COVID-19 pandemic has become the most significant challenge across the world. This challenge will be frightening especially in developing countries across the globe as it will lead to reducing imports due to disruptions in global trade, which further increases the shortages of medical supplies and other goods, resulting in a considerable price increase. The World Health Organization and UNICEF warned an alarming decline in the number of children receiving life-saving vaccines around the world. This is due to disruptions in the delivery and uptake of immunization services caused by the COVID-19 pandemic. In 2019, UNICEF procured an estimated 2.43 billion doses of vaccines to around 100 countries to reach around 45% of the world’s children below the 5-year-old age group.
Have a Call with Analyst:
Leading Companies are:
- Shanghai institute of biological products co., ltd.
- BHARAT BIOTECH
- GlaxoSmithKline plc.
- Paxvax Inc.
- PT Bio Farma
- Prokarium Ltd.
- Scandinavian Biopharma
Growing Number of Patients Suffering with Typhoid
Typhoid fever refers to a systemic infection caused by Salmonella Typhi that is usually ingested through contaminated water or food. The infectious disease is usually caused predominantly in association with lack of clean water and poor sanitization. Typhoid is known to be the most common fever in rural and underdeveloped economies. According to the recent estimates of the World Health Organization (WHO), typhoid is an endemic fever in Africa, Asia, Latin America, Oceania, and the Caribbean. The WHO also states that 80% of the typhoid fever cases arise from India, Bangladesh, China, Laos, Nepal, Indonesia, Vietnam, and Pakistan. As per the recent study by All India Institute of Medical Sciences (AIIMS), around 494 per 100,000 children of age group 5–15 years suffered from typhoid in 2017.
Buy Report at:
About The Insight Partners:
The Insight Partners is a one top industry research provider of actionable intelligence. We help our clients in getting solutions to their research requirements through our syndicated and consulting research services. We specialize in industries such as Semiconductor and Electronics, Aerospace and Defense, Automotive and Transportation, Manufacturing and Construction, Technology, Chemicals and Materials.
We offer our clients multiple ways to customize research as per their specific needs and budget.
If you have any queries about this report or if you would like further information, please contact us:
Contact Person: Sameer Joshi